Kiadis sheds half its staff as lead cell therapy bombsDutch biotech Kiadis Pharma has abandoned its lead cell therapy and axed half its workforce after a failed Share XKiadis sheds half its staff as lead cell therapy bombshttps://pharmaphorum.com/news/kiadis-sheds-half-its-staff-as-lead-cell-therapy-bombs/
UK startup Ervaxx targets ‘dark matter’ of human genomeAfter two years in stealth mode, London-based biotech Ervaxx has officially launched with $17.5 million in first-round financing Share XUK startup Ervaxx targets ‘dark matter’ of human genomehttps://pharmaphorum.com/news/uk-startup-ervaxx-targets-dark-matter-of-human-genome/
Q&A: Adaptimmune’s Elliot Norry on cell therapyDr Elliot Norry, interim chief medical officer at Adaptimmune, discusses the unique challenges of cell therapy, from manufacturing Share XQ&A: Adaptimmune’s Elliot Norry on cell therapyhttps://pharmaphorum.com/views-analysis-market-access/qa-adaptimmune-elliot-norry-on-cell-therapy/
Building cell therapy leadership in EuropeIn these videos, Markwin Velders and Louis van de Wiel of Kite, a Gilead Company, provide a behind Share XBuilding cell therapy leadership in Europehttps://pharmaphorum.com/video/building-cell-therapy-leadership-europe/
Delivering innovative therapies with close industry-NHS partnershipsIt was a crucial moment when NHS England and the National Institute for Health and Care Excellence (NICE) Share XDelivering innovative therapies with close industry-NHS partnershipshttps://pharmaphorum.com/r-d/views-analysis-r-d/delivering-innovative-therapies-with-close-industry-nhs-partnerships/
Immunicum shares fall despite “fantastic” kidney cancer dataShares in Swedish biotech Immunicum dipped sharply after it reported phase 2 results with its lead dendritic cell Share XImmunicum shares fall despite “fantastic” kidney cancer datahttps://pharmaphorum.com/news/immunicum-shares-fall-despite-fantastic-kidney-cancer-data/
Celgene strikes $1.5bn cell therapy deal with ImmaticsCelgene shows no sign of slowing down on the deal-making front as its merger with Bristol-Myers Squibb draws Share XCelgene strikes $1.5bn cell therapy deal with Immaticshttps://pharmaphorum.com/news/celgene-strikes-1-5bn-cell-therapy-deal-with-immatics/
Bayer boosts cell therapy pipeline with BlueRock acquisitionBayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes Share XBayer boosts cell therapy pipeline with BlueRock acquisitionhttps://pharmaphorum.com/news/bayer-boosts-cell-therapy-pipeline-with-bluerock-acquisition/
Finding the right reimbursement model for gene therapiesWith cell and gene therapies growing more and more important to healthcare, we sat down with Debbie Warner, Share XFinding the right reimbursement model for gene therapieshttps://pharmaphorum.com/views-and-analysis/finding-the-right-reimbursement-model-for-gene-therapies/
